Literature DB >> 23732230

Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.

J Sun1, N J Cairns2, J S Perlmutter3, R H Mach4, J Xu5.   

Abstract

The regulation of D₃ receptor has not been well documented in diffuse Lewy body disease (DLBD). In this study, a novel D₃-preferring radioligand [(3)H]WC-10 and a D₂-preferring radioligand [(3)H]raclopride were used and the absolute densities of the dopamine D₃ and D₂ receptors were determined in the striatal regions and substantia nigra (SN) from postmortem brains from five cases of DLBD, which included dementia with Lewy bodies (DLB, n=4) and Parkinson disease dementia (PDD, n=1). The densities of the dopamine D₁ receptor, vesicular monoamine transporter 2 (VMAT2), and dopamine transporter (DAT) were also measured by quantitative autoradiography using [(3)H]SCH23390, [(3)H]dihydrotetrabenazine, and [(3)H]WIN35428, respectively. The densities of these dopaminergic markers were also measured in the same brain regions in 10 age-matched control cases. Dopamine D₃ receptor density was significantly increased in the striatal regions including caudate, putamen and nucleus accumbens (NAc). There were no significant changes in the dopamine D₁ and D₂ receptor densities in any brain regions measured. VMAT2 and DAT densities were reduced in all the brain regions measured in DLB/PDD, however, the significant reduction was found in the putamen for DAT and in the NAc and SN for VMAT2. The decrease of dopamine pre-synaptic markers implies neuronal loss in the substantia nigra pars compacta (SNpc) in these DLB/PDD cases, while the increase of D₃ receptors in striatal regions could be attributed to dopaminergic medication history and psychiatric states such as hallucinations. Whether it also reflects compensatory regulation upon dopaminergic denervation warrants further confirmations on larger populations.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Parkinson disease; diffuse Lewy body disease; dopamine receptors; quantitative autoradiography

Mesh:

Substances:

Year:  2013        PMID: 23732230      PMCID: PMC3796121          DOI: 10.1016/j.neuroscience.2013.05.048

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  79 in total

1.  Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis.

Authors:  R A Sweet; R L Hamilton; M T Healy; S R Wisniewski; R Henteleff; B G Pollock; D A Lewis; S T DeKosky
Journal:  Arch Neurol       Date:  2001-03

2.  Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

Authors:  M A Piggott; E F Marshall; N Thomas; S Lloyd; J A Court; E Jaros; D Burn; M Johnson; R H Perry; I G McKeith; C Ballard; E K Perry
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

3.  Comparative Ultrastructural Analysis of D1 and D5 Dopamine Receptor Distribution in the Substantia Nigra and Globus Pallidus of Monkeys.

Authors:  Michele A Kliem; Jean-Francois Pare; Zafar U Khan; Thomas Wichmann; Yoland Smith
Journal:  Adv Behav Biol       Date:  2009-08-21

4.  Up-regulation of D3 dopamine receptor mRNA by neuroleptics.

Authors:  W Wang; K H Hahn; J F Bishop; D Q Gao; P A Jose; M M Mouradian
Journal:  Synapse       Date:  1996-07       Impact factor: 2.562

5.  BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization.

Authors:  O Guillin; J Diaz; P Carroll; N Griffon; J C Schwartz; P Sokoloff
Journal:  Nature       Date:  2001-05-03       Impact factor: 49.962

6.  Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.

Authors:  C Gagnon; B Gomez-Mancilla; R Markstein; P J Bédard; T Di Paolo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1995-07       Impact factor: 5.067

7.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.

Authors:  John E Duda; Benoit I Giasson; Meghann E Mabon; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

8.  Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.

Authors:  H L Ryoo; D Pierrotti; J N Joyce
Journal:  Mov Disord       Date:  1998-09       Impact factor: 10.338

9.  Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Authors:  A Antonini; P Vontobel; M Psylla; I Günther; P R Maguire; J Missimer; K L Leenders
Journal:  Arch Neurol       Date:  1995-12

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  14 in total

Review 1.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

Review 3.  Selectivity of probes for PET imaging of dopamine D3 receptors.

Authors:  Robert K Doot; Jacob G Dubroff; Kyle J Labban; Robert H Mach
Journal:  Neurosci Lett       Date:  2018-03-05       Impact factor: 3.046

4.  Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease.

Authors:  Samantha R Cote; Eldo V Kuzhikandathil
Journal:  Neurosci Lett       Date:  2014-11-20       Impact factor: 3.046

Review 5.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

6.  Low Dopamine D2/D3 Receptor Availability is Associated with Steep Discounting of Delayed Rewards in Methamphetamine Dependence.

Authors:  Michael E Ballard; Mark A Mandelkern; John R Monterosso; Eustace Hsu; Chelsea L Robertson; Kenji Ishibashi; Andy C Dean; Edythe D London
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-20       Impact factor: 5.176

7.  Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.

Authors:  Nicholas J Izzo; Jinbin Xu; Chenbo Zeng; Molly J Kirk; Kelsie Mozzoni; Colleen Silky; Courtney Rehak; Raymond Yurko; Gary Look; Gilbert Rishton; Hank Safferstein; Carlos Cruchaga; Alison Goate; Michael A Cahill; Ottavio Arancio; Robert H Mach; Rolf Craven; Elizabeth Head; Harry LeVine; Tara L Spires-Jones; Susan M Catalano
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

8.  Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial.

Authors:  Per Svenningsson; Anders Johansson; Dag Nyholm; Panagiota Tsitsi; Fredrik Hansson; Clas Sonesson; Joakim Tedroff
Journal:  NPJ Parkinsons Dis       Date:  2018-12-06

9.  Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains.

Authors:  Jinbin Xu; Jianjun Sun; Richard J Perrin; Robert H Mach; Kelly R Bales; John C Morris; Tammie L S Benzinger; David M Holtzman
Journal:  Ann Clin Transl Neurol       Date:  2019-07-09       Impact factor: 4.511

10.  [O-methyl-11C]N-(4-(4-(3-Chloro-2-methoxyphenyl)-piperazin-1-yl)butyl)-1H-indole-2-carboxamide ([11C]BAK4-51) Is an Efflux Transporter Substrate and Ineffective for PET Imaging of Brain D₃ Receptors in Rodents and Monkey.

Authors:  Jeih-San Liow; Cheryl L Morse; Shuiyu Lu; Michael Frankland; George L Tye; Sami S Zoghbi; Robert L Gladding; Anver B Shaik; Robert B Innis; Amy H Newman; Victor W Pike
Journal:  Molecules       Date:  2018-10-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.